Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management-Reference-Cited by-同舟云学术

Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management

Published:2021-08-17 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Verma Deepak,Firoz Amena,Garlapati Sameer Krishna Prasad,Sai Charaan Reddy Sathi Thanmay,Haris Muhammad,Dhungana Bibek,Ray Barun,Shah Gunjan,Kc Bibek,Paudel Palak

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference38 articles.

1. Cardiorenal syndrome: pathophysiology;Kumar U;Cardiol Clin,2019

2. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association;Rangaswami J;Circulation,2019

3. Diuretics in the management of cardiorenal syndrome;Chitturi C;Adv Chronic Kidney Dis,2018

4. Treatment of cardiorenal syndrome;Rubinstein J;Cardiol Clin,2019

5. Risks associated with SGLT2 inhibitors: an overview;Singh M;Curr Drug Saf,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway;European Journal of Pharmacology;2024-09

2. The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status;International Journal of Molecular Sciences;2023-09-18

3. 5) Diabetes Mellitus and Cardio-renal Linkage;Nihon Naika Gakkai Zasshi;2023-09-10

4. New Insight in Cardiorenal Syndrome: From Biomarkers to Therapy;International Journal of Molecular Sciences;2023-03-07

5. SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules;Frontiers in Nephrology;2023-01-12